Embecta Investor Lawsuit
Pomerantz Law Firm Files Class Action Against Embecta Corp. After Stock Plunge, Alleging Fraud
Embecta Corp. (NASDAQ: EMBC) lost nearly 58% of its stock value in a single day on May 5, 2026, after revealing a 14.4% drop in quarterly revenue and slashing its full-year sales outlook. The stock fell from $9.25 to $3.90, wiping out hundreds of millions in shareholder value, according to Pomerantz LLP.
Now, a federal securities class action lawsuit — Apitz-Grossman v. Embecta Corp. — has been filed against the company and its top executives. Pomerantz LLP is reminding investors that the deadline to apply as Lead Plaintiff is August 17, 2026.
CEO Called Business 'Incredibly Resolute' Weeks Before Crash
The lawsuit claims Embecta executives misled investors for months. At the 44th Annual JP Morgan Healthcare Conference on January 14, 2026, CEO Devdatt Kurdikar described the company's pen needle business as "incredibly resolute." Weeks later, that same segment posted a 14.4% revenue decline, according to Pomerantz LLP.
The class period begins November 25, 2025. Plaintiffs allege that during this time, management knew — or should have known — the company was losing market share at a "single major customer." Patients were also shifting to lower-cost retail channels where Embecta has little presence. CFO Jacob Elguicze is also named as a defendant.
Revenue Collapse and a 93% Dividend Cut Shock Shareholders
Embecta's Q2 2026 results were far worse than expected. The company had guided for revenue to be "flat to a decline of 2%." Instead, it fell 14.4% year over year. Adjusted earnings per share came in at just $0.27 — a 61% drop compared to the prior year, according to Pomerantz LLP.
The company also slashed its quarterly dividend by 93%, from $0.15 to just $0.01 per share. It cut its full-year revenue guidance by $57 million at the midpoint. CEO Kurdikar said he was "disappointed" and blamed "increased competitive dynamics and softness in overall market volumes." B of A Securities analyst Travis Steed kept an "Underperform" rating and slashed his price target from $11 to $3.
Management Blames the Market; Lawyers Blame Management
Embecta's leadership says the downturn came from broad market forces. They point to international revenue growing 2.1% and highlight a planned £150 million acquisition of Owen Mumford to diversify the business. Kurdikar has also announced a review of the company's "cost structure and organizational footprint" — a phrase that often signals layoffs.
Law firms see it differently. They argue the damage was not market-wide but was tied to a specific, predictable loss at one key customer. They say calling the business "incredibly resolute" just weeks before a crash of this size was either deliberately false or recklessly misleading — the legal standard for securities fraud.
August 17 Deadline: What Investors Need to Do Now
Investors who bought Embecta shares between November 25, 2025, and May 5, 2026, may be eligible to join the class action. The court must appoint a Lead Plaintiff by August 17, 2026. That person — typically the investor with the largest financial loss — will represent the entire group, according to Pomerantz LLP.
Investors do not need to act now to be part of any eventual settlement. But those who want to lead the case must file by the August deadline. Pomerantz LLP can be reached at 646-581-9980 or toll-free at 888-4-POMLAW. The lawsuit was filed in the U.S. District Court for the District of New Jersey.
Sentiment
NeutralPublishers
3
Articles
5
Reach
8
